Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The JAK-STAT Pathway: Impact on Human Disease and Therapeutic Intervention
John J. O’Shea, Daniella M. Schwartz, Alejandro V. Villarino, et al.
Annual Review of Medicine (2015) Vol. 66, Iss. 1, pp. 311-328
Open Access | Times Cited: 1322

Showing 1-25 of 1322 citing articles:

Inflammatory responses and inflammation-associated diseases in organs
Linlin Chen, Huidan Deng, Hengmin Cui, et al.
Oncotarget (2017) Vol. 9, Iss. 6, pp. 7204-7218
Open Access | Times Cited: 3966
Rheumatoid arthritis
Josef S Smolen, Daniel Aletaha, Iain B. McInnes
The Lancet (2016) Vol. 388, Iss. 10055, pp. 2023-2038
Open Access | Times Cited: 3691
The JAK/STAT signaling pathway: from bench to clinic
Xiaoyi Hu, Jing Li, Maorong Fu, et al.
Signal Transduction and Targeted Therapy (2021) Vol. 6, Iss. 1
Open Access | Times Cited: 1422
Small molecules in targeted cancer therapy: advances, challenges, and future perspectives
Lei Zhong, Yueshan Li, Liang Xiong, et al.
Signal Transduction and Targeted Therapy (2021) Vol. 6, Iss. 1
Open Access | Times Cited: 1127
JAK inhibition as a therapeutic strategy for immune and inflammatory diseases
Daniella M. Schwartz, Yuka Kanno, Alejandro V. Villarino, et al.
Nature Reviews Drug Discovery (2017) Vol. 16, Iss. 12, pp. 843-862
Open Access | Times Cited: 1021
Mechanisms and consequences of Jak–STAT signaling in the immune system
Alejandro V. Villarino, Yuka Kanno, John J. O′Shea
Nature Immunology (2017) Vol. 18, Iss. 4, pp. 374-384
Open Access | Times Cited: 1005
JAK–STAT Signaling as a Target for Inflammatory and Autoimmune Diseases: Current and Future Prospects
Shubhasree Banerjee, Ann Biehl, Massimo Gadina, et al.
Drugs (2017) Vol. 77, Iss. 5, pp. 521-546
Open Access | Times Cited: 937
Mechanisms of Disease: Inflammatory Bowel Diseases
Guilherme Piovezani Ramos, Konstantinos A. Papadakis
Mayo Clinic Proceedings (2019) Vol. 94, Iss. 1, pp. 155-165
Open Access | Times Cited: 772
Signaling and Function of Interleukin-2 in T Lymphocytes
Sarah H. Ross, Doreen A. Cantrell
Annual Review of Immunology (2018) Vol. 36, Iss. 1, pp. 411-433
Open Access | Times Cited: 743
The role of JAK/STAT signaling pathway and its inhibitors in diseases
Ping Xin, Xiaoyun Xu, Chengjie Deng, et al.
International Immunopharmacology (2020) Vol. 80, pp. 106210-106210
Closed Access | Times Cited: 705
The role of JAK-STAT signaling pathway and its regulators in the fate of T helper cells
Farhad Seif, Majid Khoshmirsafa, Hossein Aazami, et al.
Cell Communication and Signaling (2017) Vol. 15, Iss. 1
Open Access | Times Cited: 686
Limiting inflammation—the negative regulation of NF-κB and the NLRP3 inflammasome
Inna S. Afonina, Zhenyu Zhong, Michael Karin, et al.
Nature Immunology (2017) Vol. 18, Iss. 8, pp. 861-869
Closed Access | Times Cited: 653
Erratum to: JAK–STAT Signaling as a Target for Inflammatory and Autoimmune Diseases: Current and Future Prospects
Shubhasree Banerjee, Ann Biehl, Massimo Gadina, et al.
Drugs (2017) Vol. 77, Iss. 8, pp. 939-939
Open Access | Times Cited: 574
Type I/II cytokines, JAKs, and new strategies for treating autoimmune diseases
Daniella M. Schwartz, Michael Bonelli, Massimo Gadina, et al.
Nature Reviews Rheumatology (2015) Vol. 12, Iss. 1, pp. 25-36
Open Access | Times Cited: 552
Neutrophils as emerging therapeutic targets
Tamás Németh, Markus Sperandio, Attila Mócsai
Nature Reviews Drug Discovery (2020) Vol. 19, Iss. 4, pp. 253-275
Closed Access | Times Cited: 540
Epidermal growth factor receptor and EGFRvIII in glioblastoma: signaling pathways and targeted therapies
Zhenyi An, Ozlem Aksoy, Tina Zheng, et al.
Oncogene (2018) Vol. 37, Iss. 12, pp. 1561-1575
Open Access | Times Cited: 507
Heavy metal associated health hazards: An interplay of oxidative stress and signal transduction
Jagdish Gopal Paithankar, Sanjay Saini, Shiwangi Dwivedi, et al.
Chemosphere (2020) Vol. 262, pp. 128350-128350
Closed Access | Times Cited: 459
Harnessing the plasticity of CD4+ T cells to treat immune-mediated disease
Michel DuPage, Jeffrey A. Bluestone
Nature reviews. Immunology (2016) Vol. 16, Iss. 3, pp. 149-163
Closed Access | Times Cited: 444
Therapeutically exploiting STAT3 activity in cancer — using tissue repair as a road map
Jennifer Huynh, Ashwini L. Chand, Daniel J. Gough, et al.
Nature reviews. Cancer (2018) Vol. 19, Iss. 2, pp. 82-96
Closed Access | Times Cited: 444
JAK inhibitors in dermatology: The promise of a new drug class
William Damsky, Brett King
Journal of the American Academy of Dermatology (2017) Vol. 76, Iss. 4, pp. 736-744
Open Access | Times Cited: 427
Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial
Mark C. Genovese, Roy Fleischmann, Bernard Combe, et al.
The Lancet (2018) Vol. 391, Iss. 10139, pp. 2513-2524
Closed Access | Times Cited: 375
Upadacitinib Versus Placebo or Adalimumab in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate: Results of a Phase III, Double‐Blind, Randomized Controlled Trial
Roy Fleischmann, Aileen L. Pangan, In‐Ho Song, et al.
Arthritis & Rheumatology (2019) Vol. 71, Iss. 11, pp. 1788-1800
Closed Access | Times Cited: 356
Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial
Gerd R Burmester, Joel M. Kremer, Filip Van den Bosch, et al.
The Lancet (2018) Vol. 391, Iss. 10139, pp. 2503-2512
Open Access | Times Cited: 325
Erratum: JAK inhibition as a therapeutic strategy for immune and inflammatory diseases
Daniella M. Schwartz, Yuka Kanno, Alejandro V. Villarino, et al.
Nature Reviews Drug Discovery (2017) Vol. 17, Iss. 1, pp. 78-78
Open Access | Times Cited: 315
The potential and controversy of targeting STAT family members in cancer
Yannick Verhoeven, Sam Tilborghs, Julie Jacobs, et al.
Seminars in Cancer Biology (2019) Vol. 60, pp. 41-56
Open Access | Times Cited: 311
Page 1 - Next Page

Scroll to top